Biocryst Pharmaceuticals (BCRX) Other Non-Current Assets (2011 - 2026)

Biocryst Pharmaceuticals has reported Other Non-Current Assets for 16 years, with the latest figure at $19.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 306.12% year-over-year to $19.7 million; the trailing twelve-month figure through Mar 2026 stood at $19.7 million (up 306.12% YoY), and the FY2025 full-year result was $5.7 million, up 9.99% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $19.7 million, up from $5.7 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $19.7 million in Q1 2026, with the low at $1.8 million in Q4 2023.
• Historically, Other Non-Current Assets has averaged $7.4 million across 5 years, with a median of $6.8 million in 2022.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets slumped 80.6% — and 2026, when it soared 306.12%.
• Biocryst Pharmaceuticals' Other Non-Current Assets stood at $6.8 million in 2022, then tumbled by 73.49% to $1.8 million in 2023, then surged by 185.86% to $5.2 million in 2024, then gained by 9.99% to $5.7 million in 2025, then surged by 247.27% to $19.7 million in 2026.
• The last three Other Non-Current Assets figures came in at $19.7 million (Q1 2026), $5.7 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.